Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

Affiliations

Tsutomu Takeuchi: Keio University School of Medicine
Yoshiya Tanaka: University of Occupational and Environmental Health, Japan
Sakae Tanaka: University of Tokyo
Atsushi Kawakami: Nagasaki University Graduate School of Biomedical Sciences
Yeong-Wook Song: Seoul National University, Seoul National University Hospital
Yi-Hsing Chen: Taichung Veterans General Hospital
Mitsuhiro Rokuda: Astellas Pharma, Inc.
Hiroyuki Izutsu: Astellas Pharma, Inc.
Satoshi Ushijima: Astellas Pharma, Inc.
Yuichiro Kaneko: Astellas Pharma, Inc.
Yoshihiro Nakashima: Astellas Pharma, Inc.
Teruaki Shiomi: Astellas Pharma, Inc.
Emi Yamada: Astellas Pharma, Inc.

Abstract

An amendment to this paper has been published and can be accessed via the original article.

ISSN: 1478-6354 (Print); 1478-6362 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the musculoskeletal system
Website: https://arthritis-research.biomedcentral.com